Myriad’s riskScore Predicts Lifetime Breast Cancer Risk in Women Without Hereditary Gene Mutations

Myriad’s riskScore Predicts Lifetime Breast Cancer Risk in Women Without Hereditary Gene Mutations
Myriad Genetics has developed a new test, called riskScore, that accurately predicts the five-year and lifetime risk of breast cancer in women who tested negative for hereditary mutations in breast cancer risk genes with the myRisk Hereditary Cancer test. Results show that nearly four out of 10 patients who tested negative for hereditary breast cancer mutations have more than a 20% chance of developing breast cancer in their lifetime. The findings were recently presented at the 2017 San Antonio Breast Cancer Symposium (SABCS). The poster, titled “Development and Validation of a Combined Residual Risk Score to Predict Breast Cancer Risk in Unaffected Women Negative for Mutations on a Multi-Gene Hereditary Cancer Panel,” was presented by Elisha Hughes, PhD, senior manager of research biostatistics at Myriad Genetics. Women with a strong family history of breast cancer are often referred for genetic testing to examine whether they inherited breast cancer mutations that increase disease risk. But while there are several well-known breast cancer risk genes, fewer than 10% of women with a family history of breast cancer test positive for these mutations. RiskScore combines data from clinical risk factors, genetic markers, and a patient's family and personal history to predict individualized breast cancer risk. “Myriad Genetics is the first to bring to market a comprehensive approach to lifetime breast cancer risk assessment that includes 28 genes, family history evalua
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.